Hoth Therapeutics, Inc HOTH 深 滬
已收盤 02-06 16:00:00 美东时间
0.8082
+0.038
+4.95%
華盛通- 最 高0.815
- 今 開0.78
- 成交量 13.58万股
- 最 低 0.78
- 昨 收 0.7701
- 總市值 1253.87万
- 52周最高 2.115
- 市盈率 靜 --
- 換手率 0.88%
- 52周最低 0.6554
- 委 比 90.48%
- 總股本 1551.43万
- 歷史最高 347.00
- 量 比 0.52
- 振 幅 4.54%
- 歷史最低 0.58
- 每 手 1
- 風險率 0.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
NEW YORK, Feb. 5, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with s...
02-05 21:03
Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half
Hoth Therapeutics reported interim trial results showing all patients improved by Week 6, with reduced disease severity, fewer side effects, and early lasting benefits in cancer patients on EGFR therapy.
01-23 01:47
BRIEF-Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients
BRIEF-Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients Jan 22 (Reuters) - Hoth Therapeutics Inc HOTH.O : HOTH THERAPEUTICS DELIVERS 100% CLINICAL RESPONSE WITH ~50% REDUCTION IN DISEASE SEVERITY IN OPEN-
01-22 22:21
Hoth Therapeutics Reaches European Regulatory Milestone For HT-001 Clinical Program Targeting Cancer Patients Undergoing EGFR Inhibitor Therapies
Positive EU regulatory conclusion achievedOncology-focused clinical programMulti-country European trial footprintClear line of sight to site activation and enrollmentNear-term regulatory and operational
01-15 21:19
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Lexaria Bioscience (NASDAQ:LEXX) stock increased by 6.5% to $0.89 durin...
2025-12-17 05:05
Hoth Therapeutics Reports Pipeline Progress Across HT‑001, HT‑KIT, HT‑ALZ And New GDNF Program, Expands IP Portfolio And Partnerships
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001,
2025-12-04 03:04
Hoth Therapeutics Joins NVIDIA Connect Program To Accelerate AI-Driven Drug Development
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has been officially accepted into the NVIDIA Connect Program, a
2025-11-20 21:14
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
D. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.
2025-11-17 21:11
Hoth Therapeutics shares are trading higher after the company announced FDA Orphan Drug designation and preclinical data for HT-KIT in rare C-KIT-driven cancers
Hoth Therapeutics shares are trading higher after the company announced FDA Orp...
2025-10-21 20:28
